Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
Study sponsor: Brainstorm-Cell Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-09-29Actual
Enrollment · participants196Actual
Source updated2024-02-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.